What Happened?
Newton, AB-based Abcuro Appointed David Graaf as President and Chief Executive Officer
About the Company
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).
About the Person
David Graaf is President and Chief Executive Officer at Abcuro. Previously, David held various senior HR leadership roles in the industry.
Info Source
News
Short Profile